Human Papilloma Virus-Associated Cervical Cancer and Health Disparities
暂无分享,去创建一个
H. Banerjee | J. Philley | S. Dasgupta | Santanu Dasgupta | Patti Olusola | Hirendra Nath Banerjee | Julie V Philley | Patti Olusola
[1] Weiqin Chang,et al. The Progress of Methylation Regulation in Gene Expression of Cervical Cancer , 2018, International journal of genomics.
[2] Jing Zhang,et al. Long Non-coding RNA DLEU1 Promotes Proliferation and Invasion by Interacting With miR-381 and Enhancing HOXA13 Expression in Cervical Cancer , 2018, Front. Genet..
[3] T. Perren,et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. , 2017, The New England journal of medicine.
[4] M. Schwartz,et al. Role of HPV genotyping in risk assessment among cytology diagnosis categories: analysis of 4562 cases with cytology–HPV cotesting and follow-up biopsies , 2019, International Journal of Gynecologic Cancer.
[5] J. Berkhof,et al. Combined CADM1/MAL Methylation and Cytology Testing for Colposcopy Triage of High-Risk HPV-Positive Women , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[6] Too many women are dying from cervix cancer: Problems and solutions. , 2018, Gynecologic oncology.
[7] M. Schiffman,et al. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer , 2017, International journal of cancer.
[8] J. Tabernero,et al. New clinical trial designs in the era of precision medicine , 2019, Molecular oncology.
[9] K. Thangaraj,et al. Mitochondrial DNA variation analysis in cervical cancer. , 2014, Mitochondrion.
[10] C. Meijer,et al. Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer , 2017, Clinical Cancer Research.
[11] S. Dasgupta. Mitochondrion: I am more than a fuel server. , 2019, Annals of translational medicine.
[12] J. Xiong,et al. MicroRNA-140-5p targets insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) to suppress cervical cancer growth and metastasis , 2016, Oncotarget.
[13] J. Berkhof,et al. Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN. , 2016, Gynecologic oncology.
[14] B. Dyer,et al. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] U. Macleod,et al. Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: A systematic review. , 2017, Preventive medicine.
[16] Jian Wang,et al. BAP31, a newly defined cancer/testis antigen, regulates proliferation, migration, and invasion to promote cervical cancer progression , 2018, Cell Death & Disease.
[17] M. Jit,et al. A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls , 2013, PloS one.
[18] Xu-dong Yang,et al. Association of MBL2 exon1 polymorphisms with high-risk human papillomavirus infection and cervical cancers: a meta-analysis , 2016, Archives of Gynecology and Obstetrics.
[19] C. Iacobuzio-Donahue,et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers , 2011, Oncotarget.
[20] Oluwadamilola O Olaku,et al. Cancer in the Medically Underserved Population. , 2017, Primary care.
[21] C. Cready,et al. Race and Ethnic Disparities in Cervical Cancer Screening in a Safety-Net System , 2005, Maternal and Child Health Journal.
[22] S. Meghani,et al. Health Care‐Related Correlates of Cervical Cancer Screening among Sexual Minority Women: An Integrative Review , 2018, Journal of midwifery & women's health.
[23] Diane Solomon,et al. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. , 2013, The New England journal of medicine.
[24] L. Corey,et al. Personalized Medicine in Gynecologic Cancer: Fact or Fiction? , 2019, Obstetrics and gynecology clinics of North America.
[25] D. Miller,et al. Telomeric associations and consistent growth factor overexpression detected in giant cell tumor of bone. , 1991, Cancer genetics and cytogenetics.
[26] Nathan L. Vanderford,et al. A Social-Ecological Review of Cancer Disparities in Kentucky , 2018, Southern medical journal.
[27] M. Hoque,et al. Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. , 2008, Cancer research.
[28] D. Harper,et al. HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.
[29] Qi Zhang,et al. KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression , 2017, Scientific Reports.
[30] K. Miyamoto,et al. Aberrant DNA methylation of DLX4 and SIM1 is a predictive marker for disease progression of uterine cervical low‐grade squamous intraepithelial lesion , 2015, Diagnostic cytopathology.
[31] W. Lam,et al. Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation , 2012, Journal of cellular physiology.
[32] S. Feldman. Making sense of the new cervical-cancer screening guidelines. , 2011, The New England journal of medicine.
[33] M. Schiffman,et al. A prospective study of risk‐based colposcopy demonstrates improved detection of cervical precancers , 2018, American journal of obstetrics and gynecology.
[34] Arelis Moore de Peralta,et al. Cues to Cervical Cancer Screening Among U.S. Hispanic Women , 2017, Hispanic health care international : the official journal of the National Association of Hispanic Nurses.
[35] A. Botezatu,et al. Mitochondrial DNA mutations in patients with HRHPV-related cervical lesions. , 2011, Roumanian archives of microbiology and immunology.
[36] SaxenaAnshul,et al. Disparities in Cervical Cancer Characteristics and Survival Between White Hispanics and White Non-Hispanic Women. , 2016 .
[37] V. Tsu,et al. Saving the World's Women from Cervical Cancer. , 2016, The New England journal of medicine.
[38] S. Syrjänen,et al. From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity , 2019, Acta Cytologica.
[39] Kate L. Hertweck,et al. The Landscape of mtDNA Modifications in Cancer: A Tale of Two Cities , 2017, Front. Oncol..
[40] L. Cory,et al. ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen , 2014, Human vaccines & immunotherapeutics.
[41] Mariska Bierkens,et al. CADM1 and MAL promoter methylation levels in hrHPV‐positive cervical scrapes increase proportional to degree and duration of underlying cervical disease , 2013, International journal of cancer.
[42] A. Warowicka,et al. Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. , 2013, Gynecologic oncology.
[43] C. Fang,et al. Ethnic density and cancer: A review of the evidence , 2018, Cancer.
[44] T. Caputo,et al. Disparities in Gynecological Malignancies , 2016, Front. Oncol..
[45] Michael W Sill,et al. Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.
[46] S. Rhodes,et al. Increasing Cervical Cancer Screening Among US Hispanics/Latinas: A Qualitative Systematic Review , 2014, Journal of Cancer Education.
[47] Steven J. M. Jones,et al. Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.
[48] J. Bolin,et al. Cervical Cancer Screening Barriers and Risk Factor Knowledge Among Uninsured Women , 2017, Journal of Community Health.
[49] S. Roychowdhury,et al. Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients , 2003, Molecular pathology : MP.
[50] Elizabeth R. Unger,et al. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices , 2015, MMWR. Morbidity and mortality weekly report.
[51] J. Kahn,et al. HPV vaccination for the prevention of cervical intraepithelial neoplasia. , 2009, The New England journal of medicine.
[52] Ying Xia,et al. microRNA-328 inhibits cervical cancer cell proliferation and tumorigenesis by targeting TCF7L2. , 2016, Biochemical and biophysical research communications.
[53] HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer , 2018, Cell Death & Disease.
[54] Suping Han,et al. Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk , 2018, Medicine.
[55] A. Fader. Surgery in Cervical Cancer. , 2018, The New England journal of medicine.
[56] T. Stokke,et al. Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix , 2004, International journal of cancer.
[57] Jing Cai,et al. miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway , 2018, Cell Death & Disease.
[58] P. Rao,et al. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma , 2004, BMC Cancer.
[59] S. Yao,et al. Down-regulation of HPGD by miR-146b-3p promotes cervical cancer cell proliferation, migration and anchorage-independent growth through activation of STAT3 and AKT pathways , 2018, Cell Death & Disease.
[60] M. Mansukhani,et al. Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression , 2003, Oncogene.
[61] E. Ratner,et al. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers , 2018, Front. Oncol..
[62] Tiara Bunga Mayang Permata,et al. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy , 2018, Oncotarget.
[63] A. Umar,et al. Cancer prevention and screening: the next step in the era of precision medicine , 2019, npj Precision Oncology.
[64] Juan Li,et al. RETRACTED ARTICLE: Fibulin-3 knockdown inhibits cervical cancer cell growth and metastasis in vitro and in vivo , 2018, Scientific Reports.
[65] A. Giuliano,et al. Prevention of Invasive Cervical Cancer in the United States: Past, Present, and Future , 2012, Cancer Epidemiology, Biomarkers and Prevention.
[66] C. Iavazzo,et al. Management of ASCUS findings in Papanicolaou smears. A retrospective study. , 2012, European journal of gynaecological oncology.
[67] L. Chinula,et al. Making HPV vaccination available to girls everywhere , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[68] J. Roa,et al. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix , 2012, Clinical Epigenetics.
[69] M. Einstein,et al. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. , 2010, Gynecologic oncology.
[70] Henry C Kitchener,et al. Human papillomavirus and cervical cancer , 2013, The Lancet.
[71] S. Hur,et al. DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer , 2015, Journal of gynecologic oncology.
[72] A. Services,et al. Integrated genomic and molecular characterization of cervical cancer. , 2017 .
[73] C. Desmarais,et al. Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions , 2014, Science Translational Medicine.
[74] N. Horowitz,et al. Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival , 2018, PloS one.
[75] J. Conejo-Garcia,et al. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. , 2018, Integrative cancer science and therapeutics.
[76] M. Marino,et al. Role of Race/Ethnicity, Language, and Insurance in Use of Cervical Cancer Prevention Services Among Low-Income Hispanic Women, 2009–2013 , 2018, Preventing chronic disease.
[77] Johannes Berkhof,et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre‐)malignant cervical lesions in high‐risk HPV‐positive women , 2011, International journal of cancer.
[78] Hafiz M. R. Khan,et al. Health disparities between Black Hispanic and Black non-Hispanic cervical cancer cases in the USA. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[79] Y. Huang,et al. MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1 , 2014, British Journal of Cancer.
[80] S. Murphy,et al. Disparities in Cervical Cancer Incidence and Mortality: Can Epigenetics Contribute to Eliminating Disparities? , 2017, Advances in cancer research.
[81] N. E. Thomford,et al. Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers? , 2018, Omics : a journal of integrative biology.
[82] S. Stokley,et al. Ten Years of Human Papillomavirus Vaccination in the United States. , 2018, Academic pediatrics.
[83] X. Yi,et al. Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning , 2018, Journal of Medical Genetics.